Oppenheimer Reiterates Bullish View on Pieris Pharmaceuticals (PIRS) Following CRI Presentation

September 27, 2016 12:13 PM EDT
Get Alerts PIRS Hot Sheet
Price: $1.91 +12.35%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 19 | Down: 19 | New: 13
Trade PIRS Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Oppenheimer analyst Michelle Gilson reiterated an Outperform rating and $10 price target on Pieris Pharmaceuticals (NASDAQ: PIRS) after the company presented a poster on its wholly-owned bispecific anticalin/mAb fusion protein PRS-343 (HER2xCD137), demonstrating in vivo efficacy compared to HER2 and CD137 (4-1BB) monocloanal antibodies. Pieris anticipates to initiate Phase 1 PRS-343 (HER2xCD137) in 1H17.

Gilson commented, "The presentation at CRI highlighted (1) the flexibility of the anticalin bispecific platform, (2) tumor localized increase in human TIL in vivo, (3) selectivity in T cell activation, leading to decreased peripheral T cell activation vs. 4-1BB mAb, and decreased mortality. We believe Pieris's approach may be differentiated in its safety and efficacy, as the HER2 mAb (trastuzumab) enhances efficacy with its anti-HER2 ADCC mechanism, while targeting CD137 engagement to the tumor microenvironmet."

For an analyst ratings summary and ratings history on Pieris Pharmaceuticals click here. For more ratings news on Pieris Pharmaceuticals click here.

Shares of Pieris Pharmaceuticals closed at $1.68 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities


Add Your Comment